<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03484923</url>
  </required_header>
  <id_info>
    <org_study_id>CPDR001J2201</org_study_id>
    <secondary_id>2018-000610-38</secondary_id>
    <nct_id>NCT03484923</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma</brief_title>
  <acronym>PLATforM</acronym>
  <official_title>A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001)
      combinations in previously treated unresectable or metastatic melanoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2018</start_date>
  <completion_date type="Anticipated">June 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 19, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>4 arms are included in the randomized part of the study. One arm is included in the non-randomized part of the study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>38 months</time_frame>
    <description>ORR defined as the proportion of patients with a best overall response of either confirmed complete response or confirmed partial response (as per local review and according to RECIST v1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to disease progression or death due to any cause, whichever occurs first (3 years)</time_frame>
    <description>DOR defined as the time from date of first documented complete response or partial response to date of first documented disease progression or death due to any cause (as per local review and according to RECIST v1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to death due to any cause (3 years)</time_frame>
    <description>OS defined as time from date of randomization (or date of first dose of study treatment in arm 1A) to date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to disease progression or death due to any cause, whichever occurs first (3 years)</time_frame>
    <description>PFS defined as the interval of time between the date of randomization (or date of first dose of study treatment in arm 1A) to the date of event defined as the first documented disease progression or death due to any cause (as per local review and according to RECIST v1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to disease progression or death due to any cause, whichever occurs first (3 years)</time_frame>
    <description>DCR defined as the proportion of patients with best overall response of complete response, partial response, or stable disease (as per local review and according to RECIST v1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of anti-drug antibodies (ADA) prevalence at baseline</measure>
    <time_frame>At Baseline</time_frame>
    <description>Number of patients with presence of anti-drug antibodies (ADA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADA)</measure>
    <time_frame>Throughout study until 150 day after last drug administration</time_frame>
    <description>Number of patients developing new anti-drug antibodies (ADA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with a favorable biomarker profile (pFBP)</measure>
    <time_frame>Baseline and after 3-4 weeks on treatment</time_frame>
    <description>pFBP defined by changes in number of cells expressing the CD8+ T cell marker and/or T cell activation marker(s), T cell clonality and/or gene expression tumor biosy samples.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm 1: LAG525 + Spartalizumab in unselected patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spartalizumab and LAG525 will be administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Capmatinib+Spartalizumab in unselected patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spartalizumab will be administered intravenously. Capmatinib will be administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Canakinumab+Spartalizumab in unselected patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spartalizumab will be administered intravenously. Canakinumab will be administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: Ribociclib+Spartalizumab in unselected patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spartalizumab will be administered intravenously. Ribociclib will be administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1A: LAG525 + Spartalizumab in LAG-3 positive patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spartalizumab and LAG525 will be administered intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spartalizumab</intervention_name>
    <description>400 mg every 4 weeks intravenously (i.v)</description>
    <arm_group_label>Arm 1: LAG525 + Spartalizumab in unselected patients</arm_group_label>
    <arm_group_label>Arm 1A: LAG525 + Spartalizumab in LAG-3 positive patients</arm_group_label>
    <arm_group_label>Arm 2: Capmatinib+Spartalizumab in unselected patients</arm_group_label>
    <arm_group_label>Arm 3: Canakinumab+Spartalizumab in unselected patients</arm_group_label>
    <arm_group_label>Arm 4: Ribociclib+Spartalizumab in unselected patients</arm_group_label>
    <other_name>PDR001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAG525</intervention_name>
    <description>Taken intravenously (i.v)</description>
    <arm_group_label>Arm 1: LAG525 + Spartalizumab in unselected patients</arm_group_label>
    <arm_group_label>Arm 1A: LAG525 + Spartalizumab in LAG-3 positive patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capmatinib</intervention_name>
    <description>Taken orally</description>
    <arm_group_label>Arm 2: Capmatinib+Spartalizumab in unselected patients</arm_group_label>
    <other_name>INC280</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canakinumab</intervention_name>
    <description>Taken subcutaneusly (s.c)</description>
    <arm_group_label>Arm 3: Canakinumab+Spartalizumab in unselected patients</arm_group_label>
    <other_name>ACZ885</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib</intervention_name>
    <description>Taken orally</description>
    <arm_group_label>Arm 4: Ribociclib+Spartalizumab in unselected patients</arm_group_label>
    <other_name>LEE011</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion criteria for Arm 1,2,3,4:

          -  Histologically confirmed unresectable or metastatic stage IIIB/C/D or IV melanoma
             using AJCC edition 8

          -  Previously treated for unresectable or metastatic melanoma:

          -  Subjects with V600BRAF wild-type disease must have received prior systemic therapy for
             unresectable or metastatic melanoma with anti-PD-1/PD-L1. Additionally, subjects may
             have received anti-CTLA-4 as a single agent or in combination with anti-PD-1/PD-L1,
             irrespective of the sequence. No additional systemic treatment is allowed for advanced
             or metastatic melanoma.

        A maximum of two prior lines of systemic therapies for unresectable or metastatic melanoma
        are allowed.

        The last dose of prior therapy (anti-PD-1, anti-PD-L1 or anti-CTLA-4) must have been
        received more than four weeks before randomization.

          -  Subjects with V600BRAF mutant disease must have received prior systemic therapy for
             unresectable or metastatic melanoma with anti-PD-1/PD-L1, and V600BRAF inhibitor.
             Additionally, subjects may have received anti-CTLA-4 as a single agent or in
             combination with anti-PD-1/PD-L1, or MEK inhibitor (in combination with V600BRAF
             inhibitor or as a single agent), irrespective of the sequence. No additional systemic
             treatment is allowed for advanced or metastatic melanoma .

        A maximum of three prior lines of systemic therapies for unresectable or metastatic
        melanoma are allowed.

        The last dose of prior therapy must have been received more than 4 weeks (for anti-PD-1,
        anti-PD-L1 or anti-CTLA-4) or more than 2 weeks (for V600BRAF or MEK inhibitor) prior to
        randomization.

          -  All subjects (with V600BRAF wild-type disease and with V600BRAF mutant disease) must
             have documented disease progression as per RECIST v1.1 while on/after the last therapy
             received prior to study entry and while on/after treatment with anti-PD1/PD-L1. The
             last progression must have occured within 12 weeks prior to randomization in the
             study.

          -  ECOG performance status 0-2

          -  At least one measurable lesion per RECIST v1.1

          -  At least one lesion, suitable for sequential mandatory tumor biopsies (screening and
             on-treatment) in accordance with the biopsy guidelines specified in protocol. The same
             lesion must be biopsied sequentially.

          -  Screening tumor biopsy must fulfill the tissue quality criteria outlined in the
             protocol, as assessed by a local pathologist

        Key inclusion criteria for Arm 1A:

          -  Histologically confirmed unresectable or metastatic stage IIIB/C/D or IV melanoma
             according to AJCC Edition 8

          -  Previously treated for unresectable or metastatic melanoma:

               -  All subjects must have received anti-PD-1 checkpoint inhibitor therapy (ie.
                  pembrolizumab or nivolumab) either as monotherapy or in combination with
                  ipilimumab as the last systemic therapy prior to enrollment and must have
                  confirmed disease progression as per RECIST v1.1 (confirmed on a subsequent scan,
                  which can be the scan performed during screening) while on or after this therapy
                  prior to enrollment.

               -  Subjects with V600BRAF wild-type disease must have received no more than 2 prior
                  systemic therapies including prior anti-PD-1/PD-L1 (as monotherapy or in
                  combination with ipilimumab)

               -  Subjects with V600BRAF mutant disease must have received no more than 3 prior
                  systemic therapies including anti-PD-1/PD-L1 (as monotherapy or in combination
                  with ipilimumab), and V600BRAF inhibitor (as monotherapy or in combination with a
                  MEK inhibitor)

               -  The last dose of anti-PD-1 based therapy must have been received more than four
                  weeks prior to first dose of study treatment.

               -  The last documented disease progression must have occurred within 12 weeks prior
                  to first dose of study treatment

               -  No additional systemic treatment is allowed for advanced or metastatic melanoma
                  (this includes for example tumor infiltrating lymphocyte therapy)

          -  ECOG performance status 0-1

          -  At least one measurable lesion per RECIST v1.1

          -  Subjects must have baseline tumor sample that is positive for LAG-3 per central
             assessment

        Key exclusion criteria common to all combination arms:

          -  Subjects with uveal or mucosal melanoma

          -  Presence of clinically active or unstable brain metastasis at time of screening.

          -  Use of any live vaccines against infectious diseases within 3 months before
             randomization/enrolment.

          -  Active infection requiring systemic antibiotic therapy at time of
             randomization/enrolment.

          -  Subjects with a condition requiring systemic treatment with either corticosteroids
             (&gt;10 mg daily prednisone equivalent) or other immunosuppressive medications within 14
             days of randomization/enrollment. Inhaled or topical steroids, and adrenal replacement
             steroid doses &gt;10 mg daily prednisone equivalent, are permitted in the absence of
             active autoimmune disease.

          -  Active, known or suspected autoimmune disease or a documented history of autoimmune
             disease.

          -  Prior allogenic bone marrow or solid organ transplant

          -  History of known hypersensitivity to any of the investigational drugs used in this
             study

          -  Prior systemic therapy for unresectable or metastatic melanoma with any
             investigational agent, or with any other agent except anti-PD-1/PD-L1 and anti-CTLA-4
             (and V600BRAF and MEK inhibitors if subject has V600BRAF mutant disease). Prior
             neoadjuvant and/or adjuvant therapy for melanoma completed less than 6 months before
             the start of the study treatment

          -  Medical history or current diagnosis of myocarditis

          -  Cardiac Troponin T (or Troponin I) level &gt; 2 x ULN at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Angeles Clinic and Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Berroya</last_name>
      <phone>310-231-2122</phone>
      <email>hberroya@theangelesclinic.org</email>
    </contact>
    <investigator>
      <last_name>Omid Hamid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Striff</last_name>
      <email>estriff@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Antoni Ribas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari Oglesby</last_name>
      <phone>415-567-6600</phone>
      <email>arielle.oglesby@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Adil Daud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University/Lombardi Cancer Center CERL080AUS67</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gayle Cramer</last_name>
      <phone>202-444-1769</phone>
      <email>gc604@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Gibney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Massachusetts Gen. Hospital CC</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naika Legros</last_name>
      <phone>617-724-4000</phone>
      <email>NLEGROS@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Meghan J Mooradian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Maattala</last_name>
      <phone>617-632-5136</phone>
      <email>jennifera_maattala@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Meghan J Mooradian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Laura and Isaac Perlmutter Cancer Center Perlmutter Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-731-6160</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey S Weber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kellie Sellitto</last_name>
      <phone>412-623-4897</phone>
      <email>paladykj@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>John M. Kirkwood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de LLobregat</city>
        <state>Catalunya</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Northwood</city>
        <state>Middlesex</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>High Heaton</city>
        <state>Newcastle Upon Tyne</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 9BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2018</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unresectable</keyword>
  <keyword>melanoma</keyword>
  <keyword>metastatic melanoma</keyword>
  <keyword>advanced melanoma</keyword>
  <keyword>spartalizumab</keyword>
  <keyword>PDR001</keyword>
  <keyword>LAG525</keyword>
  <keyword>capmatinib</keyword>
  <keyword>INC280</keyword>
  <keyword>canakinumab</keyword>
  <keyword>ACZ885</keyword>
  <keyword>ribociclib</keyword>
  <keyword>LEE011</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>platform study</keyword>
  <keyword>LAG-3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

